Please assess the completion status of the following clinical trial:

Trial Title: TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the ICU after OHCA and successful CPR due to a cardiac cause~* Post anoxic coma on admission~* Ability to start study medication as soon as possible, but ultimately within 6h after OHCA via a central venous line~* Age 18 years or older~* Eligible for treatment with a target temperature management of 36⁰ C~Exclusion Criteria:~* No informed consent~* Known co-morbidity with a life expectancy of \<6 months prior to cardiac arrest~* Women aged 49 or less~* Severe cognitive impairment (documented dementia) known prior to OHCA~* Inability to insert a central venous line

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2-Iminobiotin (Type: EXPERIMENTAL): Increasing dosage of study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).